Karen, just to say my organisation is making significant progress investing resources and expertise into understanding more about Rare Diseases, and Im proud to be employed by them for that very reason.
RD is such a complex domain not least of all because there are obviously limited populations for clinical trials, which is a regulatory obligation before being able to launch therapies to market. But we are persevering!